Dr. Blackwell Discusses the HER2CLIMB Study in HER2+ Breast Cancer

Kimberly L. Blackwell, MD
Published: Tuesday, Mar 06, 2018



Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

The HER2CLIMB trial is currently investigating tucatinib (ONT-380), a novel small molecule HER2 inhibitor, in a triplet regimen (NCT02614794). Tucatinib may have the ability to penetrate the blood-brain barrier, making it a potentially beneficial option for patients with HER2-positive breast cancer who have developed brain metastases. In the study, tucatinib and trastuzumab (Herceptin) were combined with capecitabine in patients with unresectable locally advanced or metastatic HER2-positive disease with or without brain metastases.

Blackwell says that the findings of this study may provide efficacy information on whether tucatinib, as a small molecule inhibitor, might prevent progression of brain metastases when added to the regimen of capecitabine and trastuzumab.


Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

The HER2CLIMB trial is currently investigating tucatinib (ONT-380), a novel small molecule HER2 inhibitor, in a triplet regimen (NCT02614794). Tucatinib may have the ability to penetrate the blood-brain barrier, making it a potentially beneficial option for patients with HER2-positive breast cancer who have developed brain metastases. In the study, tucatinib and trastuzumab (Herceptin) were combined with capecitabine in patients with unresectable locally advanced or metastatic HER2-positive disease with or without brain metastases.

Blackwell says that the findings of this study may provide efficacy information on whether tucatinib, as a small molecule inhibitor, might prevent progression of brain metastases when added to the regimen of capecitabine and trastuzumab.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x